ROCKVILLE, MD, United States

Origene Technologies, Inc.

www.origene.com
ROCKVILLE, MD, United States
SEARCH FILTERS
Time filter
Source Type

News Article | November 3, 2016
Site: marketersmedia.com

— Increasing investment and more focus on research and development by companies for new treatment are the key factors driving the market growth. Strict rules imposed by governments across the regions is restraining genome editing market. Technological advancements generate pool of opportunities for market growth. North America captured huge market share owing to the increase in biotechnology and pharmaceutical industries in United States. However, Asia Pacific is anticipated to be the fastest growing region with highest CAGR during forecast period, because of rapid increase in research and development this region. Pharmaceutical and Biotechnology Companies in end user segment holds largest share in the market. Some of the key players in the market are Sangamo Biosciences, Inc., Origene Technologies, Inc., MERCK KGAA, Thermo Fisher Scientific, Inc., New England Biolabs, Inc., CELLECTIS S.A., Horizon Discovery Group Plc, Lonza Group Ltd., APPLIED STEMCELL INC., Sigma-Aldrich Corporation, Transposagen Biopharmaceuticals, Inc., Integrated DNA Technologies, Inc and Genscript USA Inc. Products And Services Covered: • Genome Editing Services • Software • Reagents, Enzymes and Consumables o Delivery Tools o Genome Editing Tools And Kits o Other Reagents, Enzymes And Consumables • Instruments • Cell Lines and Animal Models Technologies Covered: • Clustered Regularly Interspaced Short Palindromic Repeats (Crispr/Cas9) o Crispr Dcas9 o Wt Crispr/Cas9 o Crispr/Cas9 Nickase • Transcription Activator-Like Effector Nucleases (Talen) • Zinc Finger Nuclease (Zfn) • Antisense Technology • Other Technologies o Arcus (Homing Endonuclease) And Megatal o Recombinant Adeno-Associated Virus (R Aav) o Targatt And Rapid Trait Development System (Rtds) o Piggybac Transposase And Sleeping Beauty Transposon End Users Covered: • Pharmaceutical And Biotechnology Companies • Academic And Government Research Institutes • Plant Biotechnology Companies • Others End Users o Contract Research Organizations (Cro) o Animal Biotechnology Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/


News Article | November 22, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Genome Editing market is estimated at $2098.9 million in 2015 and is expected to reach $5367.64 million by 2022 growing at a CAGR of 14.3% from 2015 to 2022. Increasing investment and more focus  on research and development by companies for new treatment are the key factors driving the market growth. Strict rules imposed by governments across the regions is restraining genome editing market. Technological advancements generate pool of opportunities for market growth. Access the complete report at: http://www.strategymrc.com/report/genome-editing-market North America captured huge market share owing to the increase in biotechnology and pharmaceutical industries in United States. However, Asia Pacific is anticipated to be the fastest growing region with highest CAGR during forecast period, because of rapid increase in research and development this region. Pharmaceutical and Biotechnology Companies in end user segment holds largest share in the market. Some of the key players in the market are Sangamo Biosciences, Inc., Origene Technologies, Inc., MERCK KGAA, Thermo Fisher Scientific, Inc., New England Biolabs, Inc., CELLECTIS S.A., Horizon Discovery Group Plc, Lonza Group Ltd., APPLIED STEMCELL INC., Sigma-Aldrich Corporation, Transposagen Biopharmaceuticals, Inc., Integrated DNA Technologies, Inc and Genscript USA Inc. Request for a sample at: http://www.strategymrc.com/report/genome-editing-market Products And Services Covered: • Genome Editing Services • Software • Reagents, Enzymes and Consumables o Delivery Tools o Genome Editing Tools And Kits o Other Reagents, Enzymes And Consumables • Instruments • Cell Lines and Animal Models Technologies Covered: • Clustered Regularly Interspaced Short Palindromic Repeats (Crispr/Cas9) o Crispr Dcas9 o Wt Crispr/Cas9 o Crispr/Cas9 Nickase • Transcription Activator-Like Effector Nucleases (Talen) • Zinc Finger Nuclease (Zfn) • Antisense Technology • Other Technologies o Arcus (Homing Endonuclease) And Megatal o Recombinant Adeno-Associated Virus (R Aav) o Targatt And Rapid Trait Development System (Rtds) o Piggybac Transposase And Sleeping Beauty Transposon Applications Covered: • Plant Biotechnology/Agriculture • Drug Discovery and Development o Clinical o Pre-Clinical • Basic Research o Genomic Visualization o Genomic Screening o Transcription Activation/Repression • Animal Biotechnology o Livestock o Animal Health o Other Animal Biotechnology • Cell Line Engineering End Users Covered: • Pharmaceutical And Biotechnology Companies • Academic And Government Research Institutes • Plant Biotechnology Companies • Others End Users o Contract Research Organizations (Cro) o Animal Biotechnology Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain   o Rest of Europe     • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific     • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


Wesolowska N.,U.S. National Institutes of Health | Wesolowska N.,Johns Hopkins University | Amariei F.L.,U.S. National Institutes of Health | Amariei F.L.,Origene Technologies, Inc. | Rong Y.S.,U.S. National Institutes of Health
Genetics | Year: 2013

Telomeres are obligatory chromosomal landmarks that demarcate the ends of linear chromosomes to distinguish them from broken ends and can also serve to organize the genome. In both budding and fission yeast, they cluster at the periphery of the nucleus, potentially to establish a compartment of silent chromatin. To gain insight into telomere organization in higher organisms, we investigated their distribution in interphase nuclei of Drosophila melanogaster. We focused on the syncytial blastoderm, an excellent developmental stage for live imaging due to the synchronous division of the nuclei at this time. We followed the EGFP-labeled telomeric protein HOAP in vivo and found that the 16 telomeres yield four to six foci per nucleus, indicative of clustering. Furthermore, we confirmed clustering in other somatic tissues. Importantly, we observed that HOAP signal intensity in the clusters increases in interphase, potentially due to loading of HOAP to newly replicated telomeres. To determine the rules governing clustering, we used in vivo imaging and fluorescence in situ hybridization to test several predictions. First, we inspected mutant embryos that develop as haploids and found that clustering is not mediated by associations between homologs. Second, we probed specifically for a telomere of novel sequence and found strong evidence against DNA sequence identity and homology as critical factors. Third, we ruled out predominance of intrachromosomal interactions by marking both ends of a chromosome. Based on these results, we propose that clustering is independent of sequence and is likely maintained by an as yet undetermined factor. © 2013 by the Genetics Society of America.


Lee M.-H.,U.S. National Institutes of Health | Lahusen T.,U.S. National Institutes of Health | Wang R.-H.,U.S. National Institutes of Health | Xiao C.,U.S. National Institutes of Health | And 5 more authors.
Oncogene | Year: 2012

Expression of the breast cancer-associated gene 1 (BRCA1) in sporadic breast cancers is usually reduced, yet the underlying mechanisms remains elusive. To identify factors that are responsible for reduced BRCA1 expression, we screened 92 known transcription factors for their ability to regulate expression of BRCA1. Among several potential regulators, the Gli-Krueppel-related transcription factor Yin Yang 1 (YY1) showed the most dramatic transactivation of the BRCA1 promoter. YY1 binds to the promoter of BRCA1, and its overexpression resulted in increased expression of BRCA1 and a number of BRCA1 downstream genes. We further showed that overexpression of YY1 in cancer cells inhibited cell proliferation, foci formation and tumor growth in nude mice. To assess the clinical relevance between YY1 and BRCA1, we studied expression of YY1 and BRCA1 from human breast cancer samples and tissue arrays, and detected a significant positive correlation between the level of YY1 and BRCA1 expression in these cancers. Taken together, these findings suggest that YY1 is a key regulator of BRCA1 expression and may be causally linked to the molecular etiology of human breast cancer. © 2012 Macmillan Publishers Limited All rights reserved.


Trademark
Origene Technologies, Inc. | Date: 2012-07-03

monoclonal antibodies for in vitro scientific or research use.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 256.20K | Year: 2010

DESCRIPTION (provided by applicant): With its high sample density and multiplexed experimental settings, protein microarray technology is a powerful tool to study system biology at the whole proteome level. Protein microarray technology has a broad-range of utilities in biomedical research and pharmaceutical development. The most prominent application for this technology is disease biomarker discovery and in vitro diagnosis. The success of this technology fits well with NIH's mission for improving public health and developing novel methods and technologies to address unmet medical needs. Although the development of DNA microarrays has provided the technological platform for high-density microarray fabrication, the greatest challenge in assembling protein microarrays is still the acquisition of high-quality functional proteins encompassing the entire human proteome. The most comprehensive protein microarray chip currently available only includes one third of the human proteome, and furthermore, the proteins on this chip were produced in an insect cell expression system and lack appropriate mammalian posttranslational modifications. The major impediment to the application of protein microarray technology is the lack of a high-quality commercially available chip. OriGene Technologies, Inc. is a gene centric biotech company. To spearhead the human recombinant protein production market, OriGene shuttled more than 15,000 ORF cDNAs into its proprietary Eukaryotic expression system and produced 12,000 C-terminal myc- and Flag-epitope tagged human proteins in a human cell originated HEK293T cell line and validated their expression via an anti-Flag Western blot analysis. This unprecedented work has put OriGene in an enviable position to generate the best human protein microarray chip. Our extensive preliminary work also demonstrated that we will be able to generate the highest quality protein microarray chips for the research reagent market. In this Phase I application, we expect to develop a prototype high density protein microarray chip that contains 10,464 unique recombinant human proteins produced in HEK293T cells. The utilities of this protein chip will be demonstrated by detection of protein-protein interactions. The expected duration of the project is one year. Phase II of the grant will be an expansion into the commercialization of this protein chip technology, and the production of a highly purified protein microarray chip spotted with at least 20,000 unique human proteins. Multiple utilities will also be developed and optimized. We believe that this high density protein microarray chip technology will become a disruptive technology for biomedical research, as well as pharmaceutical research and development. PUBLIC HEALTH RELEVANCE: Protein microarray technology has a broad-range of utilities in biomedical research and pharmaceutical development, including disease biomarker discovery and in vitro diagnosis. The development of this technology fits well with NIH's mission for improving public health and developing novel methods and technologies to address unmet medical needs.


Patent
Origene Technologies, Inc. | Date: 2010-09-23

Illustrative embodiments herein disclosed relate to protein arrays, methods for making the arrays and methods for using them, among others. In some embodiments known proteins representing at least 50% of the loci in the human genome are arrayed in known positions on a support. In some embodiments arrays are made of proteins purified from cell lysates by affinity binding to the support. In some embodiments protein arrays are used to decode the binding specificity of antibodies. In some embodiments protein arrays are used to diagnose auto-immune disorders. Many other embodiments and general features are disclosed.


Trademark
Origene Technologies, Inc. | Date: 2012-01-23

Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs. Diagnostic agents, preparations and substances for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 1.00M | Year: 2015

Not Available


Loading Origene Technologies, Inc. collaborators
Loading Origene Technologies, Inc. collaborators